U.S. flag

An official website of the United States government

Here’s how you know
Here’s how you know

**Official websites use .gov**
A **.gov** website belongs to an official government organization in the United States.

**Secure .gov websites use HTTPS**
A **lock** ( A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Search Query:
			MAIN MENU

																				
              Health Topics
								All Health Topics A-Z
					
													
		

		Asthma


				

															Heart-Healthy Living


				

															High Blood Pressure


				

															Sickle Cell Disease


				

															Sleep Apnea


				

															Information & Resources on COVID-19
																				
              Health Education
								Education Programs and Initiatives
					
													
		

		The Heart Truth®


				

															Learn More Breathe Better®


				

															Blood Diseases and Disorders Education Program


				

															Publications and Resources
																				
              The Science
								Research Focus Areas
					
													
		

		Blood Disorders and Blood Safety


				

															Sleep Science and Sleep Disorders


				

															Lung Diseases


				

															Health Disparities and Inequities


				

															Heart and Vascular Diseases


				

															Precision Medicine Activities


				

															Obesity, Nutrition, and Physical Activity


				

															Population and Epidemiology Studies


				

															Women’s Health


				

															Research Topics


				

															Clinical Trials


				

															All Science A-Z
																				
              Grants and Training
								Grants and Training Home


				

															Policies and Guidelines


				

															Funding Opportunities and Contacts


				

															Training and Career Development
																				
              News and Events
								News and Events Home
					
													
		

		Email Alerts


				

															All News
					
													
		

		NHLBI News


				

															NHLBI in the Press


				

															Research Features


				

															All Events
					
													
		

		Past Events


				

															Upcoming Events
																				
              About NHLBI
								About NHLBI Home
					
													
		

		Mission and Strategic Vision


				

															Leadership


				

															Divisions, Offices and Centers


				

															Advisory Committees


				

															Budget and Legislative Information


				

															Jobs and Working at the NHLBI


				

															Contact and FAQs


				

															NIH Sleep Research Plan
						
						HOME
		Search Text: Home/< Back ToNHLBI Information & Resources on COVID-19/NHLBI's COVID-19 Research Strategy
0
  Researcher
      NHLBI's COVID-19 Research Strategy
        
                          Last updated July 11, 2023
NHLBI's COVID-19 Research Strategy
      MENU
            CLOSE
    
      Overview
                        Research Funding
                        Research Strategy
                        Lungs
                        Blood
                        Heart
                        For Clinicians
                        For the Public
                        Long COVID

Very soon after the COVID-19 pandemic began, the research community recognized that people who have certain underlying heart, lung, and blood diseases and conditions are at higher risk for serious health problems from infection with SARS-CoV-2, the virus that causes COVID-19. In addition, research quickly showed that COVID-19 can have potentially life-threatening effects on the heart, lungs, blood, and blood vessels.

The NHLBI’s multi-pronged research strategy aims to better our understanding of the risk of serious illness from COVID-19 and to identify therapies that will slow or halt disease progression and speed recovery.

          
COVID-19 can have severe effects on the heart, lungs, and blood

            Heart
											How COVID-19 affects the heart
										Heart inflammation, heart failure, and arrhythmias
					Learn about COVID-19 and the heart
                            Lungs
											How COVID-19 affects the lungs
										Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure
					Learn about COVID-19 and the lungs
                            Blood
											How COVID-19 affects the blood
										COVID-19 associated coagulopathy (CAC)
					Learn about COVID-19 and the blood

          
Those with underlying health conditions, such as chronic lung disease, cardiovascular disease, diabetes mellitus, and sickle cell disease, appear to be at higher risk for severe COVID-19–associated disease.
      
View a video series on how COVID-19 affects the body.

          
Research strategy goals

            The NHLBI has designed an adaptive, responsive research strategy with short- and-long-term goals. These goals include:
      
            Microscope icon
										Understand how COVID-19 causes organ dysfunction and damage, and identify potential treatments
                            Stethoscope
										Test host-directed interventions and provide an evidence base for clinical practice
                            Blood bag
										Promote blood safety, sero-surveillance, and new blood-derived therapeutics
                            Community icon
										Conduct longitudinal/cohort studies to understand natural history and risk factors
                            House icons
										Test behavioral, social, and community-based interventions
                            Icons of discs
										Provide data and biospecimen resources

          
NHLBI's rapid response

            NHLBI’s research response to the COVID-19 crisis has been a rapid, collaborative, and strategic effort.

**May 2023**

An NIH-funded RECOVER study developed a new symptom scoring system that will improve future Long COVID treatments.**February 2023**

An NIH-funded RECOVER study identified potential long COVID disparities.
	NHLBI-funded researchers found lingering symptoms are common after COVID hospitalization.
	Leaders from NIH and partner organizations outlined NIH’s COVID-19 research response in a policy forum in the journal Science.**January 2023**

NHLBI-funded researchers found COVID-19 vaccinations appeared safe for children and adolescents following multisystem inflammatory syndrome (MIS-C).**December 2022**

Two studies partially supported by NHLBI found that people with Long COVID have often reported taking longer to return to normal activities, including exercise.
	Researchers partially supported by NHLBI found a slight increase in the number of people who have experienced postural orthostatic tachycardia syndrome (POTS) following COVID-19 vaccination.**November 2022**

Two NHLBI-supported studies found that mild to moderate symptoms after a COVID-19 vaccine are normal and signal the body is learning how to respond to each virus.
	NHLBI-supported scientists found that adults with hypertension saw a small, but consequential, rise in their blood pressure levels during the first eight months of the COVID-19 pandemic.**September 2022**

Researchers supported by NHLBI and the RECOVER program found the long-term effects of COVID-19 appear uncommon in children.**June 2022**

A study supported in part by NHLBI’s HIV/AIDS research program found that breakthrough COVID infections are rare, but more common among people living with HIV/AIDS.**February 2022**

Scientists including NIH researcherspinpointed mechanisms associated with severe COVID-19 blood clotting.
	NHLBI-funded researchers foundCOVID-19 and related stress can also be blamed for an increase in blood pressureamong Americans.**January 2022**

NHLBI publishes the 2021 report on the impact of COVID-19 on heart, lung, and blood systems as part of our annual report Advancing Heart, Lung, Blood, and Sleep Research.**December 2021**

W. Keith Hoots, M.D., former director of NHLBI’s Division of Blood Disorders and Resources (DBDR), sharedinsight into how treatments that break up and prevent blood clots are helping adultsrecover from COVID-19. These treatment strategies are part of ongoing research supported by the National Institutes of Health’sAccelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)network.
	Yogen Kanthi, M.D., head of the NHLBI Laboratory of Vascular Thrombosis and Inflammation,shared his insightsinto causes of severe blood clotting in some people with COVID-19 and whether personalized treatments stop these mechanisms and speed up recovery.**October 2021**

NHLBI Director Dr. Gary Gibbons and NIMHD Director Dr. Eliseo Perez-Stable were announced as winners for the 2021 Samuel J. Heyman Service to America Medals (Sammies) in the COVID-19 Response category.NHLBI director Dr. Gary Gibbons and Eliseo Perez-Stable

**September 2021**

The NIH awarded nearly $470 million to support research as part of the RECOVER initiative, which is co-chaired by the NHLBI, to better understand the long-term effects of SARS-CoV-2 infection.**August 2021**

Results from a worldwide NHLBI clinical trial found full-dose blood thinners are effective at treating people who are hospitalized with moderate COVID-19, but not those who are seriously ill and require intensive care. Read the news release.**July 2021**

On July 26, 2021, thefederal government released guidancethat people with PASC and Long COVID can be protected under the Americans with Disabilities Act.
	Researchers discovered a pathway that may explain why some children and adolescents develop MIS-C. A clinical trial funded in part by the NHLBI is now underway using the medicine larazotide, which is in late-stage clinical trials for celiac disease.**June 2021**

Results from theNHLBI Recipient Epidemiology and Donor Evaluation Study (REDS) Program, which studies the nation’s blood supply to ensure its safety and availability,found that U.S. blood donations are safe under current COVID-19 screening guidelines.**April 2021**

The NIH awarded $29 million in additional grants for 10 more CEAL research teams and additional funding for the 11 existing CEAL research teams. These funds aim to strengthen COVID-19 vaccine confidence and access to treatment and testing.**March  2021**

The NHLBI halted the trial of COVID-19 convalescent plasma in patients with mild to moderate symptoms, after the study found that the treatment is safe but provides no significant benefit to these patients. Read the final results of the study.
	The NHLBI, as part of a trans-NIH effort, announced a research initiative to understand how SARS-CoV-2 affects children, called Collaboration to Assess Risk and Identify Long-term Outcomes for Children with COVID (CARING for Children with COVID). The research program funds studies, including the NHLBI’s MUSIC study, to find out why some children are at greater risk for infection than others, why symptoms vary among children who are infected, why some children have more severe illness than others (like multisystem inflammatory syndrome in children, or MIS-C), and what the long-term outcomes are for children who have become infected with SARS-CoV-2.**February 2021**

The NHLBI began supporting research around the trans-NIH initiative called Researching COVID to Enhance Recovery (RECOVER) to studypost-acute sequelae of SARS-CoV-2 infection (PASC). The RECOVER initiative, which includes the study of “Long COVID,” aims to understand why some patients continue to experience symptoms, or even develop new symptoms, long after SARS-CoV-2 infection seems to have ended, as well as to identify potential treatments.**October 2020**

The NHLBI announcedthe Collaborative Cohort of Cohorts for COVID-19 Research (C4R) study, to leverage NHLBI’s ongoing population-based studies to examine long-term outcomes of SARS-CoV-2 infection, as well as factors that affect risk and resilience to severe illness.
	The NHLBI also funded a five-year study to understand a rare pediatric disease associated with COVID-19, called multisystem inflammatory syndrome in children (MIS-C). The study, calledLong-TerM OUtcomes After the Multisystem Inflammatory Syndrome in Children (MUSIC), is conducted in partnership with the Pediatric Heart Network and is focusing on cardiovascular complications of MIS-C.**September 2020**

The NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities launched. The NHLBI co-leads CEAL with the National Institute of Minority Health and Health Disparities (NIMHD).NIH announced a $12 million awardfor outreach and engagement efforts in ethnically and racially diverse communities hardest hit by the COVID-19 pandemic. The award to RTI International, a non-profit research institution, supports research teams working with community partners in 11 states.**June 2020**

Based on an interim analysis, the NHLBI halted theORCHID clinical trial. The trial found that while the drug hydroxychloroquine did not cause harm, it was not beneficial to hospitalized patients with COVID-19.
	The NHLBI launched the Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS). The goal of CONNECTS is to build on NHLBI’s existing clinical research networks across the nation and around the world to better understand the risk of severe illness from COVID-19 and to identify therapies that will slow or halt the disease progression and speed recovery.
	As part of CONNECTS, the NHLBI launchedACTIV-4 Antithrombotics, a series of adaptive clinical trials evaluating the safety and effectiveness of varying doses of blood thinners to treat adults diagnosed with COVID-19. The trials involve several categories of patients — those who do not need hospitalization, those currently hospitalized, and those discharged after hospitalization for moderate to severe disease.**April 2020**

On April 9, the first patient was enrolled in an NHLBI-supported clinical trial related to COVID-19, called ORCHID, designed to test the effectiveness of the malaria drug hydroxychloroquine.
	NIH launched itstrans-NIH Accelerating COVID-19 Therapeutics Interventions and Vaccines (ACTIV) initiative, which was created to prioritize the development of new therapeutics and vaccines to address the COVID-19 pandemic. As part of this initiative, the NHLBI issued a funding opportunity announcement to bring together existing clinical trial networks focused on heart, lung, and blood disease into a united "network of networks" to focus on COVID-19.
	NIH launched theRapid Acceleration of Diagnostics (RADx)initiative, through which NHLBI supportsfour funding opportunitiesto improve COVID-19 testing in underserved and vulnerable populations (RADx Underserved Populations, RADx-UP).**March 2020**

Congress passed the Coronavirus Aid, Relief, and Economic Security (CARES) Act, authorizing $103.4 million for the NHLBI to conduct and fund COVID-19 research.
	On March 17, the NHLBI put out our first COVID-19 notice of special interest (NOSI), which called for investigators with active NHLBI grants to propose COVID-related research ranging from preclinical to clinical studies.**February 2020**

The scientific community began to recognize the systemic and multi-organ nature of COVID-19, including the extensive involvement of the heart, lung, and blood systems.
	By February, the NHLBI formed a COVID-19 response team. The NHLBI immediately began developing a research strategy, which included a process to solicit, review, and fund an initial set of clinical trials to evaluate therapies for people who become ill from COVID-19.**What’s Next**

We continue to develop new initiatives and funding opportunities, and share our findings as part of our ongoing research response strategy.

          
A Collaborative Effort

            A visual demonstrating the collaborative efforts of the COVID-19 research response, including HHS collaborations and trans-NIH efforts.NHLBI COVID-19 research response

Teams helping to design and implement the COVID response span subject areas such as preclinical studies, clinical trials, longitudinal cohort studies, community-based interventions, data mining and resources, and communications.

Pre-clinical Studies
	Clinical Trials
	Longitudinal/Cohort Studies
	Data Mining and Resources
	Communication
	Community-based Interventions
	Community-engaged ResearchThe NHLBI is working with NIH and HHS in collaboration to end the pandemic.

Trans-NIH efforts

Much of NHLBI staff are part of trans-NIH efforts that include community-based interventions to work with vulnerable populations, data coordination, and collaboration with industry.

**ACTIV Partnership** Preclinical Therapeutics Discovery, Mechanistic  
	Multi-Organ Systems  
	(Pre-clinical Studies)
	**RADx Initiative** 
	Rapid Acceleration of Diagnostics
	***Community Engagement Alliance (CEAL) Against COVID-19 Disparities****(Community-engaged Research)*
	***CARING for Children with COVID***
	***Researching COVID to Enhance Recovery (RECOVER)***
	*NIH Clinical Trial Networks
	(Clinical Trials)*
	*GWAS (Longitudinal/Cohort Studies)*
	*Data Coordination & Warehouse (Data Mining and Resources)*

HHS collaborations

At an HHS level, the NHLBI works closely with our government partners, including the FDA and CDC, and participates in working groups, such as the medical countermeasures and clinical working group. We engage in an exchange of information with patient groups to learn about their needs. The information they share helps us set our research agenda.

HHS Clinical Working Group
	HHS MCM Working Group

Links and Resources
                                    


Get the latest research information from NIH
      Get the latest public health information from CDC
      Learn more about the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)
      Learn more about the Rapid Acceleration of Diagnostics (RADx) initiative
      Read about the Community Engagement Alliance (CEAL) Against COVID-19 Disparities Back To Top Link
  

        

        Back to top
  Web Policies & Notices
  

        

              Accessibility
                      No FEAR Act Data
                      Privacy Policy
                      Freedom of Information Act (FOIA)
                      HHS Vulnerability Disclosure
    
          Related Government Websites
  

        

              Health and Human Services
                      National Institutes of Health
                      Office of the Inspector General
                      USA.gov
    
          Stay Connected
    
      
            chat bubblesLive ChatLive Chat with us, Monday through Friday, 8:30 a.m. to 5:00 p.m. EST.envelopeGet Email AlertsReceive automatic alerts about NHLBI related news and highlights from across the Institute.
  Footer Bottom
  

        



Contact Us
                            Site Index
                            Jobs